# A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

> **NCT05920356** · PHASE3 · RECRUITING · sponsor: **Amgen** · enrollment: 750 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Sotorasib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05920356
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-16
- **Primary completion:** 2027-06-30
- **Final completion:** 2032-06-29
- **Target enrollment:** 750 (ESTIMATED)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05920356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05920356, "A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05920356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*